BE XR OD vs IR BID - which Cmax for IR? [Regulatives / Guidelines]

posted by jag009  – NJ, 2020-05-11 08:29 (1532 d 04:29 ago) – Posting: # 21417
Views: 3,702

❝ I would like to have the help of the forum participants on a tricky question, ie which IR Cmax should be considered to assess the potential bioequivalence between an IR formulation administered BID and an XR formulation administered OD on day 1 and at steady-state. This is for a submission to FDA.


Not sure if the following will answer your Q exactly and whether it still exists on FDA website (or they blacked out the results):
Look for Ultram ER at Drugs@FDA.
Similar approach (Don't ask how I know :))

J

Complete thread:

UA Flag
Activity
 Admin contact
23,112 posts in 4,858 threads, 1,644 registered users;
73 visitors (0 registered, 73 guests [including 14 identified bots]).
Forum time: 12:58 CEST (Europe/Vienna)

It’s always fun to have your models validated,
but is way more fun to have them trashed.
Finding out you are completely wrong
is a great part of science.    G. Randall Gladstone

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5